Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.

Tytuł:: Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.
Autorzy:: Zhao J; Reproductive Medicine Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, People's Republic of China.
Xu B; Reproductive Medicine Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, People's Republic of China.
Huang X; Reproductive Medicine Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, People's Republic of China.
Yan Y; Reproductive Medicine Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, People's Republic of China.
Li Y; Reproductive Medicine Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, People's Republic of China. .
Źródło:: Reproductive health [Reprod Health] 2020 Nov 20; Vol. 17 (1), pp. 181. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
Język:: English
Imprint Name(s):: Original Publication: [London] : BioMed Central, 2004-
MeSH Terms:: Reproductive Techniques, Assisted*
Aromatase Inhibitors/*therapeutic use
Infertility, Female/*drug therapy
Letrozole/*therapeutic use
Ovarian Hyperstimulation Syndrome/*prevention & control
Ovulation Induction/*methods
Aromatase Inhibitors/pharmacology ; Female ; Humans ; Incidence ; Infertility, Female/etiology ; Letrozole/pharmacology ; Ovarian Hyperstimulation Syndrome/complications ; Ovarian Hyperstimulation Syndrome/epidemiology ; Ovulation Induction/adverse effects ; Pregnancy ; Pregnancy Rate
References:: Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Jul;37(7):720-4. (PMID: 22886212)
Reprod Biomed Online. 2009 Jul;19(1):8-13. (PMID: 19573285)
Reprod Biol Endocrinol. 2011 Jun 21;9:85. (PMID: 21693033)
Ann N Y Acad Sci. 2011 Mar;1221:109-18. (PMID: 21401638)
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Feb 28;44(2):158-163. (PMID: 30837384)
Reprod Biomed Online. 2009 Oct;19(4):486-92. (PMID: 19909588)
Mol Hum Reprod. 2011 Nov;17(11):679-92. (PMID: 21697218)
Obstet Gynecol Surv. 1989 Jun;44(6):430-40. (PMID: 2660037)
Fertil Steril. 1992 Aug;58(2):249-61. (PMID: 1633889)
Fertil Steril. 2009 Apr;91(4 Suppl):1611-3. (PMID: 19200960)
J Ovarian Res. 2015 Sep 23;8:63. (PMID: 26400057)
Fertil Steril. 2008 Apr;89(4):1035-6. (PMID: 18353319)
Fertil Steril. 2001 Jun;75(6):1228-30. (PMID: 11384657)
Fertil Steril. 2016 Dec;106(7):1634-1647. (PMID: 27678032)
Fertil Steril. 2009 Jul;92(1):222-5. (PMID: 18710719)
Fertil Steril. 2005 Jul;84(1):82-7. (PMID: 16009161)
Beijing Da Xue Xue Bao Yi Xue Ban. 2013 Dec 18;45(6):869-72. (PMID: 24343064)
Reprod Biomed Online. 2008 Sep;17(3):307-11. (PMID: 18764999)
Fertil Steril. 2008 Oct;90(4):1259-62. (PMID: 18163999)
Fertil Steril. 1999 Mar;71(3):482-9. (PMID: 10065786)
Fertil Steril. 1999 Feb;71(2):287-93. (PMID: 9988400)
Fertil Steril. 2000 May;73(5):883-96. (PMID: 10785212)
Fertil Steril. 2010 May 1;93(7):2281-4. (PMID: 19261278)
J Clin Invest. 1998 Dec 1;102(11):1978-85. (PMID: 9835623)
Hum Reprod. 2003 Jun;18(6):1140-1. (PMID: 12773437)
Hum Reprod. 1995 Jun;10(6):1355-8. (PMID: 7593495)
Fertil Steril. 2011 Dec;96(6):1384-1390.e4. (PMID: 21982727)
Hum Reprod. 1991 Nov;6(10):1395-9. (PMID: 1770133)
Reprod Biomed Online. 2008 Dec;17(6):751-5. (PMID: 19079957)
Fertil Steril. 2012 Mar;97(3):517-22. (PMID: 22265002)
Hum Reprod. 1995 Jun;10(6):1373-6. (PMID: 7593499)
Hum Reprod Update. 2002 Nov-Dec;8(6):559-77. (PMID: 12498425)
Syst Biol Reprod Med. 2014 Dec;60(6):355-60. (PMID: 25192259)
Am J Obstet Gynecol. 2017 Jan;216(1):42.e1-42.e10. (PMID: 27555316)
Fertil Steril. 1996 Jul;66(1):66-71. (PMID: 8752613)
Hum Reprod. 1994 May;9(5):792-9. (PMID: 7929724)
Zhonghua Fu Chan Ke Za Zhi. 2014 Dec;49(12):909-13. (PMID: 25608991)
Hum Reprod. 2001 Jan;16(1):24-30. (PMID: 11139531)
Fertil Steril. 1997 Feb;67(2):261-5. (PMID: 9022600)
Fertil Steril. 2011 Jul;96(1):53-7. (PMID: 21621772)
Fertil Steril. 1997 Jun;67(6):1038-45. (PMID: 9176441)
Semin Reprod Med. 2010 Nov;28(6):486-92. (PMID: 21082507)
Fertil Steril. 2000 Sep;74(3):429-38. (PMID: 10973633)
Grant Information:: 81401269 National Natural Science Foundation of China
Contributed Indexing:: Keywords: Assisted reproductive technologies; Letrozole; Ovarian hyperstimulation syndrome
Substance Nomenclature:: 0 (Aromatase Inhibitors)
7LKK855W8I (Letrozole)
Entry Date(s):: Date Created: 20201121 Date Completed: 20210621 Latest Revision: 20210621
Update Code:: 20240105
PubMed Central ID:: PMC7678310
DOI:: 10.1186/s12978-020-01042-2
PMID:: 33218353
: Czasopismo naukowe

Pełny tekst

Background: Letrozole can significantly decrease the estrogen level, and has been administrated to prevent the incidence of early ovary hyperstimulation syndrome (OHSS). However, the effect of Letrozole on prevention of OHSS reached to controversial conclusions. The present meta-analysis aim to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART).
Methods: An exhaustive electronic literature search was conducted on MEDLINE, Google Scholar, CNKI and WANFANG MED ONLINE, from inception until May 2018. We include clinical trials that examined the effect of Letrozole on the prevention of early OHSS. The main outcome measures were the incidence of total early OHSS, mild early OHSS, moderate early OHSS, and severe early OHSS.
Results: Eight studies included in the review. Of these, five publications evaluated the effect of Letrozolel on the prevention of total, mild, moderate, and severe OHSS, respectively. The results indicated that there was a significantly decreased incidence of total OHSS with Letrozole compared with control group, and there were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Eight studies reported the incidence of moderate + severe OHSS. We found a significant decrease in incidence of moderate + severe OHSS in high-risk women with Letrozole.
Conclusions: Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually; Letrozole should not be considered as the first-line treatment for prevention of OHSS. Further cohort studies are required to explore the effect of Letrozole on the prevention of OHSS. This study aimed to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART). A meta-analysis including 8 studies was conducted. There were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja